In deciding mifepristone case, court could safeguard FDA from judicial second-guessing
Politics, Policy & Law
Guest Commentary
Five issues the industry must face as transitions into its third act
Finance
Immunology and inflammation drug discovery company expects it can raise more capital as private company
Management Tracks
Plus: IDRx names Kerstein CMO and updates from Transgene, Noetik, Egle and MannKind
BioCentury ISSN 1097-7201